Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Fragment-based drug design facilitates selective kinase inhibitor discovery

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Application of Fragment-Based Drug Discovery to Versatile Targets

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations

Review of the Impact of Fragment-Based Drug Design on PROTAC Degrader Discovery

Fragment-based drug discovery for disorders of the central nervous system: designing better drugs piece by piece

Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

Concepts and Core Principles of Fragment-Based Drug Design

Linkers in fragment-based drug design: an overview of the literature

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

In silico construction of a focused fragment library facilitating exploration of chemical space**

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography

Using the Structural Kinome to Systematize Kinase Drug Discovery

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

Polypharmacological Drug Design Guided by Integrating Phenotypic and Restricted Fragment Docking Strategies